A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod

ObjectiveTo characterize the post-marketing safety profile of etrasimod using the latest data from the FDA Adverse Event Reporting System (FAERS), and to provide a comparative analysis versus other sphingosine-1-phosphate (S1P) receptor modulators.MethodsAE reports associated with etrasimod were ret...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yingxiu Wu, Wei Ke, Huibiao Li
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2025-11-01
Edice:Frontiers in Pharmacology
Témata:
etrasimod
FDA adverse event reporting system
disproportionality analyses
pharmacovigilance
adverse event
On-line přístup:https://www.frontiersin.org/articles/10.3389/fphar.2025.1693090/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky